Oct 24, 2025 06:20AM H.C. Wainwright Downgrades Arcturus Therapeutics (ARCT) to Neutral

Oct 23, 2025 07:27AM Citi Downgrades Arcturus Therapeutics (ARCT) to Neutral

Oct 23, 2025 06:33AM Arcturus Therapeutics (ARCT) PT Lowered to $17 at Leerink Partners

Oct 22, 2025 01:19PM Arcturus Therapeutics (ARCT) PT Lowered to $68 at Laidlaw

Sep 4, 2025 06:13AM H.C. Wainwright Starts Arcturus Therapeutics (ARCT) at Buy

Aug 12, 2025 05:59AM Arcturus Therapeutics (ARCT) PT Lowered to $42 at Wells Fargo

Aug 11, 2025 04:02PM Arcturus Therapeutics (ARCT) Misses Q2 EPS by $3.55

Jul 1, 2025 08:13AM Cantor Fitzgerald Reiterates Overweight Rating on Arcturus Therapeutics (ARCT)

Jun 30, 2025 11:00AM Arcturus Therapeutics (ARCT) Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase Deficiency Program

May 28, 2025 11:59AM Scotiabank Starts Arcturus Therapeutics (ARCT) at Sector Outperform

May 13, 2025 07:48AM Cantor Fitzgerald Reiterates Overweight Rating on Arcturus Therapeutics (ARCT)

May 13, 2025 07:19AM Arcturus Therapeutics (ARCT) PT Lowered to $66 at Canaccord Genuity

May 13, 2025 04:51AM Citi Reiterates Buy Rating on Arcturus Therapeutics (ARCT), PT $44, Opens 90-Day Positive Catalyst Watch

May 12, 2025 04:13PM Arcturus Therapeutics (ARCT) Misses Q1 EPS by 411c

Apr 11, 2025 06:37AM H.C. Wainwright Reiterates Buy Rating on Arcturus Therapeutics (ARCT)

Apr 10, 2025 08:00AM Arcturus Therapeutics (ARCT) Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1

Apr 10, 2025 07:08AM Arcturus Therapeutics (ARCT) PT Lowered to $45 at Guggenheim

Mar 27, 2025 06:07AM Arcturus Therapeutics (ARCT) PT Raised to $58 at BTIG

Mar 10, 2025 06:44AM Arcturus Therapeutics (ARCT) PT Lowered to $60 at H.C. Wainwright

Mar 10, 2025 06:29AM Arcturus Therapeutics (ARCT) PT Lowered to $68 at Canaccord Genuity

Mar 10, 2025 05:14AM BTIG Reiterates Buy Rating on Arcturus Therapeutics (ARCT)

Mar 7, 2025 05:47AM Arcturus Therapeutics (ARCT) PT Lowered to $65 at Leerink Partners

Mar 6, 2025 04:01PM Arcturus Therapeutics (ARCT) Misses Q4 EPS by 92c

Feb 18, 2025 06:47AM H.C. Wainwright Reiterates Buy Rating on Arcturus Therapeutics (ARCT)

Feb 18, 2025 05:19AM Arcturus Therapeutics (ARCT) PT Raised to $48 at BTIG

Feb 4, 2025 08:33AM Arcturus Therapeutics (ARCT) Appoints Moncef Slaoui as Chair Designate

Feb 3, 2025 06:39AM H.C. Wainwright Reiterates Buy Rating on Arcturus Therapeutics (ARCT)

Jan 28, 2025 05:12AM BTIG Starts Arcturus Therapeutics (ARCT) at Buy

Jan 7, 2025 06:53AM H.C. Wainwright Reiterates Buy Rating on Arcturus Therapeutics (ARCT)

Dec 17, 2024 06:53AM H.C. Wainwright Reiterates Buy Rating on Arcturus Therapeutics (ARCT)

Nov 11, 2024 04:01PM Arcturus Therapeutics (ARCT) Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial

Nov 11, 2024 07:12AM Arcturus Therapeutics (ARCT) PT Raised to $74 at Canaccord Genuity

Nov 7, 2024 04:05PM Arcturus Therapeutics (ARCT) Tops Q3 EPS by 31c

Oct 2, 2024 06:44AM H.C. Wainwright Reiterates Buy Rating on Arcturus Therapeutics (ARCT)

Sep 17, 2024 06:40AM Canaccord Genuity Reiterates Buy Rating on Arcturus Therapeutics (ARCT)

Sep 4, 2024 06:53AM Canaccord Genuity Reiterates Buy Rating on Arcturus Therapeutics (ARCT)

Sep 4, 2024 06:37AM William Blair Reiterates Outperform Rating on Arcturus Therapeutics (ARCT)

Sep 3, 2024 08:33AM Arcturus Therapeutics (ARCT) Receives FDA “Study May Proceed” Notice for ARCT-032

Aug 7, 2024 06:50AM Arcturus Therapeutics (ARCT) PT Raised to $63 at H.C. Wainwright

Aug 5, 2024 04:02PM Arcturus Therapeutics (ARCT) Tops Q2 EPS by 38c

Jul 15, 2024 08:43AM Piper Sandler Reiterates Overweight Rating on Arcturus Therapeutics (ARCT)

Jul 2, 2024 12:37PM Laidlaw Reiterates Buy Rating on Arcturus Therapeutics (ARCT)

Jul 2, 2024 08:19AM Piper Sandler Reiterates Overweight Rating on Arcturus Therapeutics (ARCT)

Jul 2, 2024 06:38AM H.C. Wainwright Reiterates Buy Rating on Arcturus Therapeutics (ARCT)

Jul 1, 2024 04:01PM Arcturus Therapeutics (ARCT) Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs

Jun 20, 2024 08:06AM Arcturus Therapeutics (ARCT) Appoints Moncef Slaoui to its Board